Rudy Van Den Broecke
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Rudy Van Den Broecke has a total of 22 co-authors. Here are the top co-authors by number of shared publications:
- Pieter De Visschere
Department of Radiology and Nuclear Medicine, Ghent University Hospital, Corneel Heymanslaan 10, 9000 Ghent, Belgium
3 shared publications - Hannelore Denys
Department of Medical Oncology, Ghent University Hospital, 9000 Ghent, Belgium
2 shared publications - Menekse Göker
Department of Obstetrics and Gynecology, Ghent University Hospital, Ghent, Belgium
2 shared publications - An Hendrix
Laboratory of Experimental Cancer Research, Department of Human Structure and Repair, Ghent University, Ghent, Belgium
1 shared publication - Anne-Sofie De Crem
UGent
1 shared publication - Eline Naert
Department of Medical Oncology, Ghent University Hospital, Ghent, Belgium
1 shared publication
Latest Publications
- Open Access
- 19 December 2022
- Published by Ubiquity Press, Ltd. in Journal of the Belgian Society of Radiology
- Vol. 106 (1) , 1-5
Breast Amyloidosis: A Case Report and Literature Review
Amyloidosis is an uncommon disorder characterized by extracellular accumulation of misfolded proteins in tissues. We report a unique case of localized breast amyloidosis in an asymptomatic 56-year-old woman with systemic lupus erythematosus, presented as suspicious microcalcifications without mass on mammography. Vacuum biopsy confirmed amyloidosis, producing the typical apple-green birefringence under polarized light after staining with Congo-red. Further workup and follow-up to exclude development into systemic amyloidosis or hematologic malignancy is recommended. If negative, the prognosis is very good, thus no further treatment is needed. A brief review of the literature revealed more about the typical findings and recommended management.
- 19 December 2022
- Published by Ubiquity Press, Ltd. in Journal of the Belgian Society of Radiology
- Vol. 106 (1) , 1-5
Open AccessBreast Amyloidosis: A Case Report and Literature Review
Amyloidosis is an uncommon disorder characterized by extracellular accumulation of misfolded proteins in tissues. We report a unique case of localized breast amyloidosis in an asymptomatic 56-year-old woman with systemic lupus erythematosus, presented as suspicious microcalcifications without mass on mammography. Vacuum biopsy confirmed amyloidosis, producing the typical apple-green birefringence under polarized light after staining with Congo-red. Further workup and follow-up to exclude development into systemic amyloidosis or hematologic malignancy is recommended. If negative, the prognosis is very good, thus no further treatment is needed. A brief review of the literature revealed more about the typical findings and recommended management.
- Open Access
- 20 January 2022
- Published by Elsevier in The Breast
- Vol. 62, 10-15
Safety of pre- or postoperative accelerated radiotherapy in 5 fractions: A randomized pilot trial
- 20 January 2022
- Published by Elsevier in The Breast
- Vol. 62, 10-15
Open AccessSafety of pre- or postoperative accelerated radiotherapy in 5 fractions: A randomized pilot trial
- Open Access
- 9 November 2020
- Published by Ubiquity Press, Ltd. in Journal of the Belgian Society of Radiology
- Vol. 104 (1)
B-Cell Acute Lymphoblastic Leukaemia of the Uterus
Case History A 41-year-old woman presented at the emergency department with severe metrorrhagia. It had started a few weeks ago and was gradually increasing in severity. A blood transfusion was even needed to compensate for the anaemia. A hemorrhagic myoma uteri was initially suspected on clinical examination but upon further inquiries, the patient stated she was recently diagnosed with relapsed B-cell acute lymphoblastic leukaemia (B-ALL). As a first imaging evaluation ultrasound was performed, showing a non-specific uterine enlargement. Magnetic resonance imaging (MRI) of the pelvis was added for further exploration. MRI confirmed the diffuse uterine enlargement and demonstrated a thickened, poorly defined (nearly 'washed out') junctional zone. The uterine signal was homogeneously slightly hyperintense on T2-weighted images (Figure 1) and homogeneous hypo-to isointense on T1-weighted images, with
- 9 November 2020
- Published by Ubiquity Press, Ltd. in Journal of the Belgian Society of Radiology
- Vol. 104 (1)
Open AccessB-Cell Acute Lymphoblastic Leukaemia of the Uterus
Case History A 41-year-old woman presented at the emergency department with severe metrorrhagia. It had started a few weeks ago and was gradually increasing in severity. A blood transfusion was even needed to compensate for the anaemia. A hemorrhagic myoma uteri was initially suspected on clinical examination but upon further inquiries, the patient stated she was recently diagnosed with relapsed B-cell acute lymphoblastic leukaemia (B-ALL). As a first imaging evaluation ultrasound was performed, showing a non-specific uterine enlargement. Magnetic resonance imaging (MRI) of the pelvis was added for further exploration. MRI confirmed the diffuse uterine enlargement and demonstrated a thickened, poorly defined (nearly 'washed out') junctional zone. The uterine signal was homogeneously slightly hyperintense on T2-weighted images (Figure 1) and homogeneous hypo-to isointense on T1-weighted images, with
- Open Access
- 1 May 2013
- Published by Springer Nature in SpringerPlus
- Vol. 2 (1) , 202
The addition of bevacizumab to standard chemotherapy in breast cancer: which patient benefits the most?
Bevacizumab, a humanized monoclonal antibody directed against vascular endothelial growth factor, is an effective and well-tolerated treatment option for patients with breast cancer. Bevacizumab has demonstrated a gain in progression-free survival and a trend towards an overall survival benefit in various subgroups of breast cancer. Given the lack of a predictive biomarker, we performed a literature search with regard to efficacy and tolerability of bevacizumab in different subgroups of breast cancer patients and in different settings. In the metastatic setting, the efficacy of bevacizumab has been most extensively studied and demonstrated in patients with triple-negative breast cancer, the most difficult-to-treat population among patients with advanced disease and also the group with the biggest need for new treatment options. Overall, bevacizumab is well tolerated with very few serious adverse events. Bevacizumab is also an active and feasible treatment option for patients above 70 years of age.
- 1 May 2013
- Published by Springer Nature in SpringerPlus
- Vol. 2 (1) , 202
Open AccessThe addition of bevacizumab to standard chemotherapy in breast cancer: which patient benefits the most?
Bevacizumab, a humanized monoclonal antibody directed against vascular endothelial growth factor, is an effective and well-tolerated treatment option for patients with breast cancer. Bevacizumab has demonstrated a gain in progression-free survival and a trend towards an overall survival benefit in various subgroups of breast cancer. Given the lack of a predictive biomarker, we performed a literature search with regard to efficacy and tolerability of bevacizumab in different subgroups of breast cancer patients and in different settings. In the metastatic setting, the efficacy of bevacizumab has been most extensively studied and demonstrated in patients with triple-negative breast cancer, the most difficult-to-treat population among patients with advanced disease and also the group with the biggest need for new treatment options. Overall, bevacizumab is well tolerated with very few serious adverse events. Bevacizumab is also an active and feasible treatment option for patients above 70 years of age.